The Global Syndromic Infectious Disease Diagnostics market is projected to expand at a CAGR of 4.7%, reaching USD 3.9 billion in 2031 from USD 3.1 billion in 2026.
The Syndromic Infectious Disease Diagnostics Market is growing steadily due to rising demand for rapid, multiplex diagnostic solutions. These platforms detect multiple pathogens simultaneously, improving treatment decisions and patient outcomes. Increasing infectious disease burden and advancements in molecular diagnostics are key factors supporting global market expansion.
Multiplex molecular platforms are used for diagnosing syndromic infectious diseases through the identification of multiple pathogens from one specimen based upon symptoms rather than utilizing individual assays. These systems are prevalent in laboratory testing for bacteria and virus infections, primarily in three areas: respiratory infections, gastrointestinal infections, and bloodstream infections. While the use of PCR and Next Generation Sequencing provides analytical sensitivity and rapid turnaround (most results are available on the same day as testing, often within one hour), they have reduced unnecessary antibiotic prescribing while improving the clinical decision-making process. As such, these assays are essential to the success of modern healthcare systems.
Rising Rate of Infectious Illnesses: With more people being hit by respiratory, gastrointestinal, and sexually transmitted infections than ever before, there is an increase in demand for diagnostic tests that provide quick results.
Need for Rapid & Accurate Test Results: Healthcare professionals need test results rapidly in order to provide the best care possible. Trends indicate that syndromic testing provides much quicker turnaround times as compared with traditional culture-based diagnostic methods.
Technology Advances in Multiplex Testing: Technological Developments in the multiplex PCR and sequencing test methods are allowing for the assembly and use of many different tests simultaneously. Providing an accurate result at the fastest speed allows hospital systems to use syndromic testing much more than they did in the past.
A Push Toward Antibiotic Stewardship: Accurate identification of the causative pathogen in an infected patient can help healthcare providers use their antibiotics only when necessary. A global response to preventing the growth of antimicrobial-resistant organisms relies on identifying pathogens with accuracy.
The market faces several challenges, which include, but are not limited to: the high costs associated with multiplex diagnostic systems, reimbursement issues, and lack of trained personnel to use these systems. There are also opportunities within the marketplace with the expansion of point-of-care syndromic testing, greater adoption of these technologies in emerging markets and the potential for integration with artificial intelligence-based analytic technologies. As healthcare entities emphasize the use of rapid, reliable diagnostic technology, we anticipate that syndromic testing systems will play a significant role in the management of infectious diseases.
June 2025: bioMérieux strengthened its antimicrobial resistance diagnostics capabilities by acquiring assets from Day Zero Diagnostics, a company specialising in genome sequencing and machine learning-based infectious disease detection. This acquisition enables faster identification of pathogens and their antibiotic resistance profiles directly from blood samples, significantly reducing diagnostic time from days to hours.
The market is segmented by product type, technology, application and geography.
The kits and reagents account for the majority of this market, as these products are necessary for performing multiplex syndromic tests in labs and in clinical settings. These kits include assay panels that provide clinicians with an opportunity to test for multiple pathogens from one specimen. Because these items are routinely used by hospitals and laboratories, the demand for them remains consistent. The growth of syndromic testing has prompted companies to design and manufacture very specific reagent panels for respiratory, gastrointestinal and bloodstream infections. The use of these kits also facilitates shorter turnaround times and increased sensitivity, thus critical in delivering accurate diagnoses and supporting effective management of patients being treated for infectious diseases.
PCR technology is the predominant technology used in syndromic diagnostics. This is due to the high sensitivity and specificity of PCR, as well as the fact that PCR is the fastest technology available today. PCR multiplex panel tests can detect several pathogens at once in less than an hour's time. The importance of this technology lies in its ability to help physicians identify co-infections and tailor treatment accordingly. In addition, PCR's reliability and extensive use in clinical laboratory testing make it the foundation of syndromic testing. Ongoing development and innovation in real-time and multiplex PCR will continue to enhance the efficiency of diagnostics and help to fuel the development of this market.
The application of clinical diagnostics is the largest quantity of syndromic testing. Clinical diagnostics primarily uses syndromic testing platforms within hospitals and diagnostic laboratories to provide care for patients. With the ability to perform a multiplex test and get results in less time than traditional methods, clinicians can quickly know the cause of infections so that they can provide timely and appropriate treatment. The ability to detect multiple pathogens in a single test allows for quicker diagnostic results and improved patient outcomes.
The North American market is the largest market owing to an advanced healthcare system, many successful government programs, and high utilisation of diagnostic technologies. The increase in drug-resistant infections and the presence of key companies will support the North American region with the largest revenue share.
South America is gradually moving toward the adoption of more advanced diagnostic solutions as total health infrastructure continues to improve. The growing prevalence of infectious diseases is expected to increase demand for AMR diagnostics in the South American region.
Europe shows steady growth driven by increasing infectious disease burden, strong healthcare systems, and supportive regulatory frameworks.
Early-stage adoption of wearable biosensors within the Middle East and Africa (MEA) is motivated by improved healthcare accessibility and increasing interest in technical advancements for portable diagnostics.
Asia-Pacific is the fastest-growing region due to a large population, rising infection rates, and increasing healthcare investments. Expansion of diagnostic infrastructure is accelerating adoption.
· Thermo Fisher Scientific
· Roche Diagnostics
· Bio-Rad Laboratories
· QIAGEN
· Danaher Corporation
· Abbott Laboratories
· bioMérieux
· Bruker Corporation
· Accelerate Diagnostics
· Hologic
Abbott leads the market for wearable biosensors, particularly in the area of continuous glucose monitoring (CGM). Their FreeStyle Libre system has become the standard against which all others are compared, allowing patients with diabetes to monitor their blood sugar levels in real time without the hassle of repeatedly pricking their fingers. Abbott is working to combine biosensors with mobile platforms, so patients have an ongoing picture of their health status based on this continuous data. Abbott's highly developed global footprint, commitment to innovation and development of digital health ecosystems through partnerships have helped them cement their position as the leader in wearable diagnostics.
BioMérieux is a top provider of diagnostic services for both infectious diseases and testing for resistance against antibiotics. Through its combined offerings of automated systems, test reagents and software, bioMérieux's products allow hospitals and/or laboratories to perform rapid identification of microorganisms as well as provide the test results necessary for initiating the most appropriate and effective treatment options for patients with an infectious disease. In addition, bioMérieux places a strong emphasis on developing innovative technologies and techniques to enhance the ability to accurately and quickly detect infections via microbiological as well as molecular diagnostic methods. bioMerieux's extensive global reach, coupled with its expertise in the discipline of infectious disease, uniquely position bioMérieux to assist in the drive to advance AMR diagnostic products and services and, subsequently, improve global healthcare delivery.
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 3.1 billion |
| Total Market Size in 2031 | USD 3.9 billion |
| Forecast Unit | Billion |
| Growth Rate | 4.7% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Product Type, Technology, Application, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|